| NCT05696717 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-27 | 2028-01 | 2026-01 |
| NCT05165485 | Phase 4 COPD and Suboptimal Inspiratory Flow Rate | COMPLETED | PHASE4 | 2022-01-07 | 2023-11-20 | 2023-11-13 |
| NCT05091723 | TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation | COMPLETED | PHASE1 | 2021-10-13 | 2021-11-24 | 2021-11-24 |
| NCT04688632 | Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | COMPLETED | PHASE1 | 2021-01-18 | 2021-03-26 | 2021-03-13 |
| NCT04587713 | Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects | COMPLETED | PHASE1 | 2020-10-16 | 2020-12-27 | 2020-12-24 |
| NCT04589260 | TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis | TERMINATED | PHASE1 | 2020-10-15 | 2021-10-04 | 2021-05-06 |
| NCT03920254 | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | TERMINATED | PHASE2, PHASE3 | 2020-07-23 | 2021-10-27 | 2021-10-27 |
| NCT04402866 | TD-0903 for ALI Associated With COVID-19 | COMPLETED | PHASE2 | 2020-06-24 | 2021-04-21 | 2021-04-21 |
| NCT04350736 | First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 | COMPLETED | PHASE1 | 2020-04-23 | 2020-07-01 | 2020-06-24 |
| NCT04200573 | Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | COMPLETED | PHASE1 | 2020-01-13 | 2021-08-19 | 2021-08-19 |
| NCT04150341 | Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response | COMPLETED | PHASE2 | 2019-11-06 | 2020-09-03 | 2020-08-28 |
| NCT04095793 | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | TERMINATED | PHASE3 | 2019-09-19 | 2021-11-12 | 2021-11-12 |
| NCT04044339 | Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects | COMPLETED | PHASE1 | 2019-08-08 | 2019-11-27 | 2019-11-27 |
| NCT03758443 | Efficacy & Safety of TD-1473 in Ulcerative Colitis | TERMINATED | PHASE2, PHASE3 | 2019-03-11 | 2021-10-20 | 2021-10-20 |
| NCT03829657 | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | TERMINATED | PHASE3 | 2019-02-22 | 2021-11-10 | 2021-11-10 |
| NCT03750552 | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | COMPLETED | PHASE3 | 2019-01-24 | 2021-07-21 | 2021-07-21 |
| NCT03750565 | Multiple Dose Ethnobridging PK Study in Healthy Subjects | COMPLETED | PHASE1 | 2018-11-27 | 2019-02-13 | 2019-02-13 |
| NCT03635112 | Efficacy and Safety of TD-1473 in Crohn's Disease | TERMINATED | PHASE2 | 2018-11-19 | 2021-12-30 | 2021-12-30 |
| NCT03652038 | Single and Multiple Ascending Dose Study of TD-8236 by Inhalation | COMPLETED | PHASE1 | 2018-11-07 | 2020-07-13 | 2020-07-13 |
| NCT03555617 | Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study | COMPLETED | PHASE1 | 2018-06-13 | 2018-07-15 | 2018-07-15 |
| NCT03432793 | Drug-Drug Interaction (DDI) Study for TD-9855 | COMPLETED | PHASE1 | 2018-02-28 | 2018-04-21 | 2018-04-21 |
| NCT03408470 | TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects | COMPLETED | PHASE1 | 2018-01-31 | 2018-02-21 | 2018-02-21 |
| NCT02705755 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | COMPLETED | PHASE2 | 2017-09-09 | 2018-11-28 | 2018-07-24 |
| NCT03103412 | TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) | COMPLETED | PHASE1 | 2017-05-04 | 2017-11-08 | 2017-11-08 |
| NCT02954263 | Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects | COMPLETED | PHASE1 | 2016-11 | 2017-04 | 2017-02 |
| NCT02818686 | TD-1473 for Active Ulcerative Colitis (UC) | COMPLETED | PHASE1 | 2016-10-03 | 2018-03-29 | 2018-03-29 |
| NCT02903095 | Single Ascending Dose Study of TD-1439 in Healthy Subjects | COMPLETED | PHASE1 | 2016-09 | 2017-02 | 2016-12 |
| NCT02709928 | Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects | COMPLETED | PHASE1 | 2016-03 | 2016-12 | 2016-11 |
| NCT02663089 | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects | COMPLETED | PHASE1 | 2016-02-08 | 2016-03-17 | 2016-03-17 |
| NCT02657122 | SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects | COMPLETED | PHASE1 | 2015-12 | 2016-04 | 2016-04 |
| NCT02639078 | Single Ascending Dose Study of TD-0714 in Healthy Subjects | COMPLETED | PHASE1 | 2015-11 | 2016-02 | 2016-02 |
| NCT02267525 | The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study | COMPLETED | PHASE2 | 2014-12 | 2017-06 | 2017-06 |
| NCT02116543 | TD-6450 MAD Study in HCV Infected Subjects | COMPLETED | PHASE1 | 2014-05 | 2014-11 | 2014-10 |
| NCT02022306 | TD-6450 SAD and MAD in Healthy Subjects | COMPLETED | PHASE1 | 2014-02 | 2014-09 | 2014-08 |
| NCT01924143 | TD-9855 Mass Balance Study | COMPLETED | PHASE1 | 2013-10 | 2013-12 | 2013-11 |
| NCT01949103 | TD-1607 MAD Study in Healthy Subjects | COMPLETED | PHASE1 | 2013-10 | 2014-07 | 2014-06 |
| NCT01791049 | TD-1607 SAD Study in Healthy Subjects | COMPLETED | PHASE1 | 2013-04 | 2013-10 | 2013-08 |
| NCT01718938 | Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | COMPLETED | PHASE2 | 2012-12 | 2014-02 | 2013-12 |
| NCT01693692 | Phase 2 Study of TD-9855 to Treat Fibromyalgia | COMPLETED | PHASE2 | 2012-11 | 2014-04 | 2014-01 |
| NCT01702194 | TD-1211 IV/Oral Mass Balance Study | COMPLETED | PHASE1 | 2012-11 | 2013-03 | 2013-02 |
| NCT01644240 | A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects | TERMINATED | PHASE1 | 2012-09 | 2012-12 | 2012-11 |
| NCT01655771 | TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects | COMPLETED | PHASE1 | 2012-08 | 2013-03 | 2013-02 |
| NCT01568411 | A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211 | COMPLETED | PHASE1 | 2012-04 | 2012-06 | 2012-06 |
| NCT01458340 | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2011-12 | 2013-11 | 2013-10 |
| NCT01459926 | A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation | COMPLETED | PHASE2 | 2011-11 | 2012-06 | 2012-05 |
| NCT01401985 | A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) | COMPLETED | PHASE2 | 2011-10 | 2012-08 | 2012-05 |
| NCT01333540 | A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation | COMPLETED | PHASE2 | 2011-05 | 2012-06 | 2012-05 |
| NCT01040637 | A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation | COMPLETED | PHASE1, PHASE2 | 2010-01 | 2010-10 | 2010-10 |
| NCT00674817 | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. | COMPLETED | PHASE2 | 2008-04-01 | 2008-10-19 | 2008-10-01 |
| NCT00687700 | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers | COMPLETED | PHASE1 | 2008-03-10 | 2008-05-27 | 2008-05-27 |
| NCT00550225 | Succinate Salt Version of GSK961081 for Healthy Volunteers | COMPLETED | PHASE1 | 2007-11-29 | 2008-01-08 | 2008-01-08 |
| NCT00442832 | TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection | COMPLETED | PHASE2 | 2006-12 | 2007-05 | 2007-05 |
| NCT00887406 | Study of GSK961081 in Healthy Volunteer Subjects | COMPLETED | PHASE1 | 2005-11-07 | 2006-10-04 | 2006-10-04 |